-+ 0.00%
-+ 0.00%
-+ 0.00%
ACE Private Equity Invests in Danish Drug Ingredient Maker Chr. Olesen Synthesis
Share
Listen to the news
ACE Private Equity Invests in Danish Drug Ingredient Maker Chr. Olesen Synthesis
  • ACE Private Equity invested in Chr. Olesen Synthesis in an acquisition led by Samfara, announced Nov. 17, 2026.
  • Denmark-based Olesen manufactures controlled-substance active pharmaceutical ingredients used primarily in opioid addiction and ADHD treatments for generic drugmakers globally.
  • Growth opportunities include expanding production capacity, launching adjacent products and pursuing selective acquisitions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ace & Company SA published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending